...
search icon
sana-img

Sana Biotechnology Inc, Common Stock

SANA

NSQ

$3.41

+$0.04

(1.19%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$768.04M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.85M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.44
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.52 L
$12 H
$3.41

About Sana Biotechnology Inc, Common Stock

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameSANASectorS&P500
1-Week Return16.78%3.54%-0.58%
1-Month Return111.8%7.51%1.89%
3-Month Return-13.01%-0.85%3.24%
6-Month Return-44.55%-1.67%10.09%
1-Year Return-42.98%5.2%22.09%
3-Year Return-57.69%13.08%35.68%
5-Year Return-90.28%44.4%83.47%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue3.92M10.17M17.91M27.73M30.86M[{"date":"2019-12-31","value":12.7,"profit":true},{"date":"2020-12-31","value":32.95,"profit":true},{"date":"2021-12-31","value":58.04,"profit":true},{"date":"2022-12-31","value":89.85,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(3.92M)(10.17M)(17.91M)(27.73M)(30.86M)[{"date":"2019-12-31","value":-392100000,"profit":false},{"date":"2020-12-31","value":-1017100000,"profit":false},{"date":"2021-12-31","value":-1791400000,"profit":false},{"date":"2022-12-31","value":-2773100000,"profit":false},{"date":"2023-12-31","value":-3086500000,"profit":false}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses141.15M286.15M356.91M272.56M294.94M[{"date":"2019-12-31","value":39.55,"profit":true},{"date":"2020-12-31","value":80.17,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":76.37,"profit":true},{"date":"2023-12-31","value":82.64,"profit":true}]
Operating Income(141.15M)(286.15M)(356.91M)(272.56M)(326.90M)[{"date":"2019-12-31","value":-14115200000,"profit":false},{"date":"2020-12-31","value":-28614900000,"profit":false},{"date":"2021-12-31","value":-35690900000,"profit":false},{"date":"2022-12-31","value":-27256400000,"profit":false},{"date":"2023-12-31","value":-32690000000,"profit":false}]
Total Non-Operating Income/Expense5.68M1.59M1.66M6.85M53.58M[{"date":"2019-12-31","value":10.61,"profit":true},{"date":"2020-12-31","value":2.97,"profit":true},{"date":"2021-12-31","value":3.09,"profit":true},{"date":"2022-12-31","value":12.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(138.32M)(285.31M)(355.93M)(269.48M)(283.25M)[{"date":"2019-12-31","value":-13832500000,"profit":false},{"date":"2020-12-31","value":-28530500000,"profit":false},{"date":"2021-12-31","value":-35592800000,"profit":false},{"date":"2022-12-31","value":-26947600000,"profit":false},{"date":"2023-12-31","value":-28325500000,"profit":false}]
Income Taxes(7.55M)(6.67M)(11.75M)(3.09M)-[{"date":"2019-12-31","value":-754700000,"profit":false},{"date":"2020-12-31","value":-666800000,"profit":false},{"date":"2021-12-31","value":-1174600000,"profit":false},{"date":"2022-12-31","value":-308800000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes(130.78M)(278.64M)(344.18M)(266.39M)-[{"date":"2019-12-31","value":-13077800000,"profit":false},{"date":"2020-12-31","value":-27863700000,"profit":false},{"date":"2021-12-31","value":-34418200000,"profit":false},{"date":"2022-12-31","value":-26638800000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(130.78M)(285.31M)(355.93M)(269.48M)(283.25M)[{"date":"2019-12-31","value":-13077800000,"profit":false},{"date":"2020-12-31","value":-28530500000,"profit":false},{"date":"2021-12-31","value":-35592800000,"profit":false},{"date":"2022-12-31","value":-26947600000,"profit":false},{"date":"2023-12-31","value":-28325500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(130.78M)(278.64M)(344.18M)(266.39M)(283.25M)[{"date":"2019-12-31","value":-13077800000,"profit":false},{"date":"2020-12-31","value":-27863700000,"profit":false},{"date":"2021-12-31","value":-34418200000,"profit":false},{"date":"2022-12-31","value":-26638800000,"profit":false},{"date":"2023-12-31","value":-28325500000,"profit":false}]
EPS (Diluted)-(7.90)(1.83)(1.69)(1.41)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-789.91,"profit":false},{"date":"2021-12-31","value":-183,"profit":false},{"date":"2022-12-31","value":-169,"profit":false},{"date":"2023-12-31","value":-141,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

SANA
Cash Ratio 4.23
Current Ratio 4.47

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

SANA
ROA (LTM) -31.15%
ROE (LTM) -92.90%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

SANA
Debt Ratio Lower is generally better. Negative is bad. 0.48
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.52

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

SANA
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 2.58
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Sana Biotechnology Inc share price today?

Sana Biotechnology Inc (SANA) share price today is $3.41

Can Indians buy Sana Biotechnology Inc shares?

Yes, Indians can buy shares of Sana Biotechnology Inc (SANA) on Vested. To buy Sana Biotechnology Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SANA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Sana Biotechnology Inc be purchased?

Yes, you can purchase fractional shares of Sana Biotechnology Inc (SANA) via the Vested app. You can start investing in Sana Biotechnology Inc (SANA) with a minimum investment of $1.

How to invest in Sana Biotechnology Inc shares from India?

You can invest in shares of Sana Biotechnology Inc (SANA) via Vested in three simple steps:

  • Click on Sign Up or Invest in SANA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Sana Biotechnology Inc shares
What is Sana Biotechnology Inc 52-week high and low stock price?

The 52-week high price of Sana Biotechnology Inc (SANA) is $12. The 52-week low price of Sana Biotechnology Inc (SANA) is $1.52.

What is Sana Biotechnology Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Sana Biotechnology Inc (SANA) is 2.58

What is the Market Cap of Sana Biotechnology Inc?

The market capitalization of Sana Biotechnology Inc (SANA) is $768.04M

What is Sana Biotechnology Inc’s stock symbol?

The stock symbol (or ticker) of Sana Biotechnology Inc is SANA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top